Obesity and Digestive Disease Unit, Medica Sur Clinic and Foundation, Puente de Piedra 150, Toriello Guerra, 14050 Mexico City, Mexico.
Obesity and Digestive Disease Unit, Medica Sur Clinic and Foundation, Puente de Piedra 150, Toriello Guerra, 14050 Mexico City, Mexico.
Med. 2024 May 10;5(5):375-376. doi: 10.1016/j.medj.2024.03.013.
The most important factor associated with liver-related mortality in NAFLD is liver fibrosis. There is no approved treatment for metabolic dysfunction-associated steatohepatitis (MASH) or liver fibrosis. In the MAESTRO-NASH trial, Harrison et al. demonstrated the efficacy of resmetirom, a selective THR-β agonist, for the treatment of MASH and liver fibrosis at 52 weeks.
与非酒精性脂肪性肝病相关的肝死亡率最重要的因素是肝纤维化。目前还没有针对代谢功能障碍相关脂肪性肝炎（MASH）或肝纤维化的批准治疗方法。在 MAESTRO-NASH 试验中，Harrison 等人证明了选择性 THR-β激动剂 resmetirom 在 52 周时治疗 MASH 和肝纤维化的疗效。
